Germline pathogenic variants in Mexican patients with hereditary triple-negative breast cancer

Objective. Describe the prevalence of breast cancer (BC)- associated germline pathogenic variants (PVs) among Mexican patients with triple-negative BC (TNBC). Materials and methods. The spectrum of PVs identified among patients with TNBC who were enrolled in a prospective registry and underwent gene...

Full description

Bibliographic Details
Main Authors: Yanin Chavarri-Guerra, Cynthia Villarreal-Garza, Ana S Ferrigno, Alejandro Mohar, Dione Aguilar, Rosa M Alvarez-Gomez, Lenny Gallardo-Alvarado, Azucena del Toro-Valero, Gregorio Quintero-Beulo, Francisco Gutierrez-Delgado, José Luis Rodriguez-Olivares, Maria Fernanda Ochoa-Chavez, Gubidxa Gutierrez-Seymour, Danielle Castillo, Josef Herzog, Jeffrey N Weitzel
Format: Article
Language:English
Published: Instituto Nacional de Salud Pública 2022-02-01
Series:Salud Pública de México
Subjects:
Online Access:https://www.saludpublica.mx/index.php/spm/article/view/12704
Description
Summary:Objective. Describe the prevalence of breast cancer (BC)- associated germline pathogenic variants (PVs) among Mexican patients with triple-negative BC (TNBC). Materials and methods. The spectrum of PVs identified among patients with TNBC who were enrolled in a prospective registry and underwent genetic testing was analyzed. Results. Of 387 patients with invasive TNBC and a median age at diagnosis of 39 years (range 21-72), 113 (29%) were carriers of PVs in BC-susceptibility genes: BRCA1 (79%), BRCA2 (15%), and other (6%: ATM, BRIP1, PALB2, PTEN, RAD51C, and TP53). PV carriers were younger at BC diagnosis (37 vs. 40 years, p=0.004) than non-carriers. Conclusion. A large proportion of TNBC in Mexican patients is associated with germline PVs, the vast majority in BRCA. The incremental yield of PVs in other BC-susceptibility genes was modest, and a stepwise approach starting with BRCA testing may be justified if it is more cost-effective than multigene panel testing.
ISSN:0036-3634